These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 21819802

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Evidence-based therapeutic drug monitoring for saquinavir].
    Muret P, Solas C, Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.
    Therapie; 2011; 66(3):207-12. PubMed ID: 21819804
    [Abstract] [Full Text] [Related]

  • 4. [Not Available].
    Muret P, Piedoux S, Solas C, Quaranta S, pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.
    Therapie; 2011; 66(3):187-95. PubMed ID: 27393198
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [Abstract] [Full Text] [Related]

  • 12. Nevirapine in the treatment of HIV.
    Milinkovic A, Martínez E.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):367-73. PubMed ID: 15482202
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, Gorowara M, Yamada N, Yanai H, Mitarai S, Ishikawa N, Cooper DA, Phanuphak P, Burger D, Ruxrungtham K.
    Antivir Ther; 2008 Jun; 13(4):529-36. PubMed ID: 18672531
    [Abstract] [Full Text] [Related]

  • 18. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E, Paredes R, Bonjoch A, Tuldrà A, Fumaz CR, Gel S, Garcés B, Johnston S, Arnó A, Balagué M, Jou A, Tural C, Sirera G, Romeu J, Cruz L, Francia E, Domingo P, Arrizabalaga J, Ruiz I, Arribas JR, Ruiz L, Clotet B.
    Antivir Ther; 1999 Jun; 4 Suppl 3():23-8. PubMed ID: 16021868
    [Abstract] [Full Text] [Related]

  • 19. [Combined antiretroviral therapy with nevirapine of HIV-infected adults].
    Kravchenko AV.
    Ter Arkh; 2004 Jun; 76(11):68-71. PubMed ID: 15658542
    [No Abstract] [Full Text] [Related]

  • 20. [Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
    MMW Fortschr Med; 2005 Apr 25; 147 Spec No 1():42-3. PubMed ID: 16385872
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.